Compare Amgen, Inc. (AMGN) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs IQIYI Inc - ADR — how do they compare? Amgen, Inc. trades at $415.21 (market cap $224.14B), while IQIYI Inc - ADR trades at $1.37 (market cap $1.30B). The key difference: Amgen, Inc. is far larger — about 172.4× IQIYI Inc - ADR's market cap, and Amgen, Inc. pays a 2.43% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| AMGN | IQ | |
|---|---|---|
Market Cap | $224.14B | $1.30B |
Sector | Health | Media |
52-Week High | $417.20 | $2.79 |
52-Week Low | $271.18 | $0.96 |
Enterprise Value | $267.45B | $2.88B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
iQIYI (IQ) trades at $1.36, up 2.26% today, with a bullish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion. Valuation ratios show a high P/E of 144.05 but attractive P/S of 0.33 and P/B of 0.67. Recent news highlights AI platform growth and leadership changes, with Q2 2026 earnings due August 18, 2026.
The outlook is mixed: analyst consensus is 50% buy, but profitability challenges and revenue declines pose risks. Upside potential exists from AI initiatives and cost controls, yet competitive pressures and regulatory uncertainty in China remain headwinds. The stock offers speculative value for turnaround bets, balanced by fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
